Drug intelligence / Profile preview

V8

Development stage: Phase 2
Lead developer: Immunitor
Modality: Cell Therapies
Administration: Oral

Overview

V8 is a biological intervention developed by Immunitor LLC, currently in Phase II clinical trials for treating kidney failure. It aims to induce immune tolerance through the oral delivery of kidney cells, thereby addressing inflammatory renal disease caused by the host's immune response against itself. Preliminary studies have shown promising results without adverse side effects.

Beyond the preview

Go deeper on V8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V8.

Explore the full profile